|
Gene: SLC9A7 |
Gene summary for SLC9A7 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SLC9A7 | Gene ID | 84679 |
Gene name | solute carrier family 9 member A7 | |
Gene Alias | MRX108 | |
Cytomap | Xp11.3 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | A0A087WXD1 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
84679 | SLC9A7 | HCC1_Meng | Human | Liver | HCC | 3.82e-34 | 3.88e-02 | 0.0246 |
84679 | SLC9A7 | HCC2_Meng | Human | Liver | HCC | 1.20e-02 | 2.54e-02 | 0.0107 |
84679 | SLC9A7 | HCC1 | Human | Liver | HCC | 1.15e-18 | 4.59e+00 | 0.5336 |
84679 | SLC9A7 | HCC2 | Human | Liver | HCC | 1.65e-09 | 2.50e+00 | 0.5341 |
84679 | SLC9A7 | S027 | Human | Liver | HCC | 1.21e-11 | 7.46e-01 | 0.2446 |
84679 | SLC9A7 | S028 | Human | Liver | HCC | 2.35e-23 | 6.84e-01 | 0.2503 |
84679 | SLC9A7 | S029 | Human | Liver | HCC | 4.47e-18 | 6.47e-01 | 0.2581 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:19026007 | Liver | HCC | proton transmembrane transport | 87/7958 | 157/18723 | 7.27e-04 | 4.42e-03 | 87 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC9A7 | SNV | Missense_Mutation | novel | c.916C>A | p.Gln306Lys | p.Q306K | protein_coding | tolerated(0.13) | probably_damaging(0.954) | TCGA-37-4130-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
SLC9A7 | SNV | Missense_Mutation | novel | c.2015C>T | p.Thr672Ile | p.T672I | protein_coding | tolerated(0.07) | possibly_damaging(0.776) | TCGA-MT-A7BN-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
SLC9A7 | SNV | Missense_Mutation | c.1408N>G | p.Leu470Val | p.L470V | protein_coding | deleterious(0) | benign(0.343) | TCGA-BR-4280-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
SLC9A7 | SNV | Missense_Mutation | c.1351N>A | p.Val451Ile | p.V451I | protein_coding | tolerated(0.78) | benign(0) | TCGA-BR-4363-01 | Stomach | stomach adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
SLC9A7 | SNV | Missense_Mutation | c.458N>G | p.Tyr153Cys | p.Y153C | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BR-8368-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
SLC9A7 | SNV | Missense_Mutation | c.186N>T | p.Glu62Asp | p.E62D | protein_coding | tolerated(0.36) | benign(0.019) | TCGA-CD-8536-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Chemotherapy | epirubicin | CR | ||
SLC9A7 | insertion | Frame_Shift_Ins | novel | c.1698_1699insT | p.Asp567Ter | p.D567* | protein_coding | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD | |||
SLC9A7 | insertion | Nonsense_Mutation | novel | c.1697_1698insCTTATTCTGAG | p.Gln566HisfsTer4 | p.Q566Hfs*4 | protein_coding | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |